newsfilter
← Latest News
PR Newswire·

Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting

-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a